Cerus (NASDAQ:CERS) CFO Sells $55,869.96 in Stock

Cerus Corporation (NASDAQ:CERS) CFO Kevin Dennis Green sold 27,796 shares of the company’s stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $2.01, for a total transaction of $55,869.96. Following the sale, the chief financial officer directly owned 1,168,095 shares of the company’s stock, valued at approximately $2,347,870.95. This trade represents a 2.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Kevin Dennis Green also recently made the following trade(s):

• On Thursday, March 5th, Kevin Dennis Green sold 55,225 shares of Cerus stock. The shares were sold at an average price of $2.06, for a total transaction of $113,763.50.

Cerus Stock Up 1.1%

Shares of CERS opened at $1.79 on Thursday. The firm has a 50 day simple moving average of $2.30 and a two-hundred day simple moving average of $1.86. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.73 and a quick ratio of 1.17. Cerus Corporation has a one year low of $1.12 and a one year high of $2.96. The company has a market cap of $343.98 million, a P/E ratio of -22.38 and a beta of 1.51.

Cerus (NASDAQ:CERS) last issued its earnings results on Monday, March 2nd. The biotechnology company reported ($0.01) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.01). Cerus had a negative return on equity of 26.09% and a negative net margin of 7.58%.The firm had revenue of $64.58 million for the quarter, compared to the consensus estimate of $59.31 million. Research analysts forecast that Cerus Corporation will post -0.08 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Cibc World Markets Corp bought a new position in Cerus during the 4th quarter worth $25,000. MML Investors Services LLC bought a new stake in shares of Cerus in the 4th quarter valued at about $37,000. Caitong International Asset Management Co. Ltd increased its stake in shares of Cerus by 68.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 18,712 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 7,603 shares during the period. Bingham Private Wealth LLC acquired a new stake in shares of Cerus in the fourth quarter valued at about $40,000. Finally, CIBC Bancorp USA Inc. bought a new position in shares of Cerus during the third quarter worth about $31,000. 78.37% of the stock is owned by institutional investors.

Analysts Set New Price Targets

CERS has been the topic of a number of recent analyst reports. Wall Street Zen cut Cerus from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. TD Cowen restated a “buy” rating on shares of Cerus in a research note on Monday, January 12th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold”.

Cerus Company Profile

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.